The Latest Cardiac and Vascular News
A short induction of Remodulin® (treprostinil) injection allowed study subjects to reach double the typical doses of Orenitram® (treprostinil) extended-release tablets than patients who did not have a Remodulin induction SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation […]
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results […]
SHANGHAI, Sept. 20, 2022 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, today released the positive results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study on Transcatheter Cardiovascular Therapy conference (TCT 2022),one of the world’s most influential cardiovascular conference. PADN is an […]
SHANGHAI, Sept. 7, 2022 /PRNewswire/ — A globally recognized OTM innovative platform Pulnovo Medical Limited’s proprietary Pulmonary Artery Denervation (PADN) technology has been included in the 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of pulmonary arterial hypertension (PAH) (hereinafter referred to as “the […]
First approval of a dry powder inhaler for treatment of PAH and PH-ILD DPI device represents a convenient option for administration of treprostinil therapy Commercial launch activities underway; patient availability expected in June 2022 SILVER SPRING, Md. & RESEARCH TRIANGLE […]
TNX-201 (oral imatinib modified release tablets) Formulation Development has been Successfully Completed Manufacturing Underway to Support Phase 3 PAH Study (IMPROVE) MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that […]
– Strong preclinical data shows that C21 reverses vascular remodelling – Proof-of-concept trial in pulmonary arterial hypertension (“PAH”) planned to start late 2022 – Appointment of two new senior clinical advisors in PAH GOTHENBURG, Sweden, March 9, 2022 /PRNewswire/ — Vicore Pharma Holding […]
Ethics Committee Approval is Final Step Prior to Enrollment of Claritas’ Phase 1 Clinical Study of R-107 SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) — Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” […]
MINNEAPOLIS, Nov. 23, 2021 /PRNewswire/ — VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced today that the company has raised a convertible […]
Unique, Delayed-Release Formulation of Imatinib Designed to Avoid Gastric Intolerance On Track to Initiate a Single Phase 3 in PAH in 2Q 2022 Recently Updated Company Website Highlights Imatinib Clinical Program MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical […]
